B
JBIO

Braidwell’s Jade Biosciences JBIO Stock Holding History

Braidwell’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-41,157
Closed -$3.62M – 57
2025
Q1 		$3.62M Hold
41,157
– – 0.13% 60
2024
Q4 		$3.82M Buy
+41,157
New +$3.55M 0.11% 68

Other funds holding JBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Braidwell's JBIO Position: Q2 2025 in Review

Braidwell sold out of Jade Biosciences (JBIO) in Q2 2025, closing a stake of 41,157 shares — an estimated $3.62M sold.

Braidwell first reported a position in JBIO in Q4 2024 and held it in 2 quarters. The position peaked at $3.82M in Q4 2024. 75 funds tracked by Wall St. Rank hold JBIO as of Q2 2025.

  • Braidwell reported no remaining Jade Biosciences position as of Q2 2025 after selling out during the quarter.
  • Braidwell sold 41,157 Jade Biosciences shares in Q2 2025, an estimated $3.62M.
  • Braidwell first reported a position in Jade Biosciences in Q4 2024 and held it in 2 quarters.
  • Braidwell's Jade Biosciences position peaked at $3.82M in Q4 2024.
  • 75 funds tracked by Wall St. Rank held Jade Biosciences as of Q2 2025.

Based on Braidwell's 13F filing for Q2 2025, filed 14 Aug 2025.